29-Jul-2021 | Facts and Factors
Findings from the report “Adult Hemoglobinopathy Testing Market By Variant Type (Variant A2, and Variant F), By Test Type (HPLC Test, Mass Spectrometry, and Hemoglobin Electrophoresis), End-User (Hospitals, Reference Laboratories, and Academic & Medical Institutes): Global & Regional Industry Perspective, Comprehensive Analysis, and Forecasts, 2021 – 2026” states that the global adult hemoglobinopathy testing market in 2020 was approximately USD 330 Million. The market is expected to grow at a CAGR of 3.9% and is anticipated to reach around USD 430 Million by 2026.
Hemoglobinopathy is caused by genetic abnormalities and anemia. Structure defects in the hemoglobin molecule decreased synthesis of one of the two subunits of the hemoglobin molecule, and pathological interactions of normally usual subunits both contribute to the development of irregular hemoglobin. Extreme and mild diseases are the two forms of disorders. As a result of these mutations, the formation of the haemoglobin (Hb) molecule is slowed or its structure is changed. Hemoglobinopathy is a condition caused by the presence of variant haemoglobin in red blood cells. As a result of a variety of government-provided health facilities, such as payment systems for therapies and diagnostic tests, as well as the treatment of existing hemoglobinopathy patients, the global adult hemoglobinopathy testing market is projected to expand at a rapid rate. Non-governmental organisations are also focusing their efforts on using innovative diagnostic methods for hemoglobinopathy diagnosis. Adult hemoglobinopathy is also on the increase globally, owing to factors like NGO and government collaboration to develop more advanced testing approaches, the gradual proliferation of point-of-care evaluation methods, and low-cost therapies.
Browse the full report “Adult Hemoglobinopathy Testing Market By Variant Type (Variant A2, and Variant F), By Test Type (HPLC Test, Mass Spectrometry, and Hemoglobin Electrophoresis), End-User (Hospitals, Reference Laboratories, and Academic & Medical Institutes): Global & Regional Industry Perspective, Comprehensive Analysis, and Forecasts, 2021 – 2026” at https://www.fnfresearch.com/adult-hemoglobinopathy-testing-market
Due to the incidences of sickle cell disease, thalassemia, and other hemoglobinopathies, the adult hemoglobinopathy testing market is expected to grow over the forecast period. Policymakers' growing support for measuring and monitoring diseases related to blood, as well as technological advancements, have an effect on the industry. The emerging area is expected to provide opportunities for the industry to expand during the forecast era. The global market is expected to face some difficulties, which may restrict its development. The lack of understanding about hemoglobinopathy disorders and testing in numerous developing and underdeveloped emerging economies is likely to curtail the growth of the market. The lack of advanced screening technology procedures such as genetic testing, the complexity of hemoglobinopathy tests, and the disease's increasing prevalence may restrain the market's growth.
COVID-19 started in Wuhan, China, in December of 2019 and has rapidly spread around the world since then. Proper treatment and management of Coronavirus (COVID-19) infection in patients affected by adult Hematological testing may be difficult, particularly in some countries, given the rapid spread of the pandemic and the scarcity of study. Various projects are attempting to produce papers with indications for the health care of these patients at this crucial juncture. Adult hemoglobinopathy research companies should seize this chance. COVID-19 has also opened up a slew of potential opportunities for private companies to enter the industry and meet the significant challenge. Aside from that, as an alternative to conventional tests, software that measures hemoglobinopathy testings automatically is gaining prominence. Adult hemoglobinopathy testing technology is now being used to assess the efficacy of current drugs as a possible therapy, and is stimulating market development due to the recent occurrence of coronavirus disease (COVID-19) and the lack of an adequate vaccination or remedy. The COVID-19 pandemic has helped the growth of the adult hemoglobinopathy testing research industry. Adult hemoglobinopathy study is used to find new COVID-19 drug candidates and to determine the cell model. As a result, in 2020, demand for adult hemoglobinopathy testing research is expected to rise, boosting market share.
The global adult hemoglobinopathy testing market is bifurcated into its variant type, test type, end-user, and regions. Based on the variant type, the global market is divided into variant A2, and variant F. Based on test type, the market is bifurcated into HPLC test, mass spectrometry, and hemoglobin electrophoresis. Based on the end-user, the market is segmented into reference laboratories, hospitals, and academic & medical institutes. Geographically, the global market is bifurcated into North America, Asia-Pacific, Europe, Middle East & Africa, and Latin America.
Europe currently dominates the global adult hemoglobinopathy research industry and is anticipated to continue its dominance in the upcoming years. The Asia Pacific is expected to grow faster than the rest of the world during the forecast period, owing to the rising prevalence of hemoglobinopathy in countries such as India and China. According to the World Health Organization, Sickle Cell Anemia is a public health issue that is most common in African and Sub-Asian countries. As a result of the influx of people from the infected countries moving to North America and Europe, the number of new instances of hemoglobinopathy disorders diagnosed has increased. As a result of growing migration, the market in central and northern Europe, especially Germany, is expected to boom. Similarly, the amount of hemoglobinopathy cases observed in North America has risen as a consequence of growing migration from Asia, fueling the hemoglobinopathy testing market growth in the upcoming years. Policymakers also launched a number of public health programs, such as genetic tests, diagnostic facilities, and counseling, in response to increasing hemoglobinopathy genotypes, which would continue to drive the global market during the forecast period.
Top Market Players
Some of the key players in the adult hemoglobinopathy testing market are Chromsystems Instruments & Chemicals GmbH, PerkinElmer Inc., CapitalBio Technology Inc., Bio-Rad Laboratories, Inc., BioMedomics, Inc., Streck, Inc., Thermo Fisher Scientific Inc., Trinity Biotech, Baxter, and Bluebird Bio among others.
This report segments the adult hemoglobinopathy testing market as follows:
Global Adult Hemoglobinopathy Testing Market: By Variant Type Segmentation Analysis
Global Adult Hemoglobinopathy Testing Market: By Test Type Segmentation Analysis
- HPLC Test
- Mass Spectrometry
- Hemoglobin Electrophoresis
Global Adult Hemoglobinopathy Testing Market: By End User Segmentation Analysis
- Reference Laboratories
- Academic & Medical Institutes
Global Adult Hemoglobinopathy Testing Market: Regional Segmentation Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Facts & Factors
A 2108, Sargam,
Pune 411041, India